Pharmacokinetics of recombinant human erythropoietin in children with renal failure

Abstract

The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEpo; 40 units/kg1) were investigated in children (9-16 years) with end-stage renal failure. After an intravenous (i.v.) dose, serum rHuEpo concentrations declined in a monoexponential manner with a mean half-life (t1/2) of 5.6 +/- 3 h (+/- SEM; n = 9). Serum clearance and the apparent… (More)
DOI: 10.1007/BF00878377

Topics

  • Presentations referencing similar topics